References: Anticoagulation for venous thromboembolism (VTE) in patients with obesity

  • Mocini D, Di Fusco SA, Mocini E, Donini LM, Lavalle C, Di Lenarda A, et al. Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO). J Clin Med 2021;10(18). https://www.ncbi.nlm.nih.gov/pubmed/34575306
  • Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost 2021. https://www.ncbi.nlm.nih.gov/pubmed/34259389
  • Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009;43(6):1064-83. https://www.ncbi.nlm.nih.gov/pubmed/19458109
  • Rondina MT, Wheeler M, Rodgers GM, Draper L, Pendleton RC. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. Thromb Res 2010;125(3):220-3. https://www.ncbi.nlm.nih.gov/pubmed/19272635